First Patient Dosed with LIXTE’s LB-100 and GSK’s Immunotherapy Dostarlimab-gxly in Ovarian Clear Cell Carcinoma Trial

January 29, 2024

https://www.globenewswire.com/news-release/2024/01/29/2818900/0/en/First-Patient-Dosed-with-LIXTE-s-LB-100-and-GSK-s-Immunotherapy-Dostarlimab-gxly-in-Ovarian-Clear-Cell-Carcinoma-Trial.html

PASADENA, CA, Jan. 29, 2024 (GLOBE NEWSWIRE) — LIXTE Biotechnology Holdings, Inc. (Nasdaq:LIXT and LIXTW) (“LIXTE” or the “Company”), today announced the dosing of the first patient in a Phase 1b/2 clinical trial to assess whether adding LIXTE’s LB-100 to GSK’s programmed death receptor-1 (PD-1)-blocking monoclonal antibody, dostarlimab-gxly, may enhance the effectiveness of immunotherapy in the treatment of ovarian clear cell carcinoma (OCCC).

Read more at globenewswire.com

Related news for (LIXT)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.